| Original language | English |
|---|---|
| Pages (from-to) | 1434-1443 |
| Number of pages | 10 |
| Journal | Journal of the European Academy of Dermatology and Venereology |
| Volume | 35 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published (VoR) - Jul 2021 |
Funding
Dr. Ross reports personal fees from GSK Pharma, Mycovia and Nabriva Therapeutics as well as ownership of shares in GSK Pharma and AstraZeneca Pharma; and is author of the UK and European Guidelines on Pelvic Inflammatory Disease; is a Member of the European Sexually Transmitted Infections Guidelines Editorial Board; is a Member of the National Institute for Health Research Funding Committee (Health Technology Assessment programme). He is an NIHR Journals Editor and associate editor of Sexually Transmitted Infections journal. He is an officer of the International Union against Sexually Transmitted Infections (treasurer), and a charity trustee of the Sexually Transmitted Infections Research Foundation. Dr. Kreuter reports personal fees from InfectoPharm, Paul‐Ehrlich‐Gesellschaft für Chemotherapie e.V., DERFO ‐ Dermatologische Fortbildungs‐Gesellschaft, MSD SHARP & DOHME, Böhringer Ingelheim, and MSD SHARP & DOHME, all outside the submitted work. Dr. de Vries reports grants from Gilead, personal fees from Novartis, outside the submitted work. The other authors declare no conflict of interest.